AMS’ JetTouch has the potential to enable needle-free injection into any area of the body reachable by endoscopic or percutaneous access.
Under the co-development agreement, AMS will first develop JetTouch for general use in the bladder.
Botox is currently under the US Food and Drug Administration (FDA) review as a potential treatment for overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients, who are intolerant of an anticholinergic medication.
Endo Health Solutions chief scientific officer and R&D executive vice president Ivan Gergel said, "With AMS’ position in the urology marketplace, the potential of the JetTouch system combined with the delivery of BOTOX make this a mutually beneficial business opportunity."
In August 2011, Botox was approved by the FDA for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults, who are intolerant of an anticholinergic medication.
